TransMedics Group, Inc. (NASDAQ: TMDX) Stock Competitors & Peer Comparison

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ABT has a market cap of 191.9B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ABT trades at $110.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ABT's P/E ratio is 21.29. In terms of profitability, TMDX's ROE is +0.33%, compared to ABT's ROE of +0.11%. Regarding short-term risk, TMDX is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ABT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, TMDX's ROE is +0.33%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, TMDX is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BSX-PA's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SYK has a market cap of 133.1B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SYK trades at $347.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SYK's P/E ratio is 25.93. In terms of profitability, TMDX's ROE is +0.33%, compared to SYK's ROE of +0.16%. Regarding short-term risk, TMDX is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check SYK's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, MDT has a market cap of 116.2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while MDT trades at $90.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas MDT's P/E ratio is 16.41. In terms of profitability, TMDX's ROE is +0.33%, compared to MDT's ROE of +0.10%. Regarding short-term risk, TMDX is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check MDT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BSX has a market cap of 76.4B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BSX trades at $51.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BSX's P/E ratio is 16.58. In terms of profitability, TMDX's ROE is +0.33%, compared to BSX's ROE of +0.15%. Regarding short-term risk, TMDX is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BSX's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, EW has a market cap of 53.6B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while EW trades at $93.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas EW's P/E ratio is 34.46. In terms of profitability, TMDX's ROE is +0.33%, compared to EW's ROE of +0.10%. Regarding short-term risk, TMDX is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check EW's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, DXCM has a market cap of 34.3B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while DXCM trades at $90.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas DXCM's P/E ratio is 38.97. In terms of profitability, TMDX's ROE is +0.33%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, TMDX is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check DXCM's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, RMD has a market cap of 32.8B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while RMD trades at $226.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas RMD's P/E ratio is 20.99. In terms of profitability, TMDX's ROE is +0.33%, compared to RMD's ROE of +0.24%. Regarding short-term risk, TMDX is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check RMD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, PHG has a market cap of 26.2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while PHG trades at $26.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas PHG's P/E ratio is 15.32. In terms of profitability, TMDX's ROE is +0.33%, compared to PHG's ROE of +0.10%. Regarding short-term risk, TMDX is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check PHG's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ZBH has a market cap of 18.9B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ZBH trades at $97.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ZBH's P/E ratio is 11.54. In terms of profitability, TMDX's ROE is +0.33%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, TMDX is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ZBH's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ABMD's P/E ratio is 65.36. In terms of profitability, TMDX's ROE is +0.33%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, TMDX is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ABMD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while PEN trades at $326.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas PEN's P/E ratio is 85.30. In terms of profitability, TMDX's ROE is +0.33%, compared to PEN's ROE of +0.11%. Regarding short-term risk, TMDX is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check PEN's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SWAV's P/E ratio is 78.76. In terms of profitability, TMDX's ROE is +0.33%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, TMDX is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SWAV's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SNN has a market cap of 12.5B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SNN trades at $29.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SNN's P/E ratio is 14.05. In terms of profitability, TMDX's ROE is +0.33%, compared to SNN's ROE of +0.12%. Regarding short-term risk, TMDX is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SNN's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ALGN has a market cap of 12.5B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ALGN trades at $174.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ALGN's P/E ratio is 15.86. In terms of profitability, TMDX's ROE is +0.33%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, TMDX is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ALGN's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while GMED trades at $85.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas GMED's P/E ratio is 19.30. In terms of profitability, TMDX's ROE is +0.33%, compared to GMED's ROE of +0.12%. Regarding short-term risk, TMDX is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check GMED's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, GKOS has a market cap of 11B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while GKOS trades at $186.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas GKOS's P/E ratio is -216.86. In terms of profitability, TMDX's ROE is +0.33%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, TMDX is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check GKOS's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, PODD has a market cap of 10B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while PODD trades at $145.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas PODD's P/E ratio is 24.71. In terms of profitability, TMDX's ROE is +0.33%, compared to PODD's ROE of +0.27%. Regarding short-term risk, TMDX is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PODD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BIO has a market cap of 9.8B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BIO trades at $362.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BIO's P/E ratio is 39.04. In terms of profitability, TMDX's ROE is +0.33%, compared to BIO's ROE of +0.03%. Regarding short-term risk, TMDX is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BIO's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BIO-B trades at $348.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BIO-B's P/E ratio is 103.33. In terms of profitability, TMDX's ROE is +0.33%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, TMDX is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check BIO-B's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas MASI's P/E ratio is 44.43. In terms of profitability, TMDX's ROE is +0.33%, compared to MASI's ROE of +0.09%. Regarding short-term risk, TMDX is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check MASI's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BRKR has a market cap of 9B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BRKR trades at $59.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BRKR's P/E ratio is 29.78. In terms of profitability, TMDX's ROE is +0.33%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, TMDX is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BRKR's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas NARI's P/E ratio is -59.24. In terms of profitability, TMDX's ROE is +0.33%, compared to NARI's ROE of -0.00%. Regarding short-term risk, TMDX is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check NARI's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while LIVN trades at $80.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas LIVN's P/E ratio is 19.19. In terms of profitability, TMDX's ROE is +0.33%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, TMDX is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check LIVN's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ITGR trades at $125.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ITGR's P/E ratio is 19.70. In terms of profitability, TMDX's ROE is +0.33%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, TMDX is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ITGR's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, HAE has a market cap of 4.2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while HAE trades at $91.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas HAE's P/E ratio is 18.23. In terms of profitability, TMDX's ROE is +0.33%, compared to HAE's ROE of +0.11%. Regarding short-term risk, TMDX is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check HAE's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while IRTC trades at $125.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas IRTC's P/E ratio is -195.86. In terms of profitability, TMDX's ROE is +0.33%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, TMDX is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check IRTC's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas AXNX's P/E ratio is -709.80. In terms of profitability, TMDX's ROE is +0.33%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, TMDX is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check AXNX's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, AXGN has a market cap of 2.7B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while AXGN trades at $49.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas AXGN's P/E ratio is 130.71. In terms of profitability, TMDX's ROE is +0.33%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, TMDX is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check AXGN's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BFLY trades at $9.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BFLY's P/E ratio is -39.35. In terms of profitability, TMDX's ROE is +0.33%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, TMDX is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BFLY's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while UFPT trades at $322.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas UFPT's P/E ratio is 32.94. In terms of profitability, TMDX's ROE is +0.33%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, TMDX is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check UFPT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ESTA trades at $75.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ESTA's P/E ratio is -59.98. In terms of profitability, TMDX's ROE is +0.33%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, TMDX is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ESTA's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas NUVA's P/E ratio is 75.00. In terms of profitability, TMDX's ROE is +0.33%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, TMDX is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check NUVA's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while NVCR trades at $17.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas NVCR's P/E ratio is -11.50. In terms of profitability, TMDX's ROE is +0.33%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, TMDX is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check NVCR's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while INSP trades at $58.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas INSP's P/E ratio is 25.67. In terms of profitability, TMDX's ROE is +0.33%, compared to INSP's ROE of +0.18%. Regarding short-term risk, TMDX is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check INSP's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while TNDM trades at $23.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas TNDM's P/E ratio is -21.31. In terms of profitability, TMDX's ROE is +0.33%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, TMDX is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check TNDM's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CNMD trades at $49.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CNMD's P/E ratio is 10.89. In terms of profitability, TMDX's ROE is +0.33%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, TMDX is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CNMD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ATEC trades at $9.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ATEC's P/E ratio is -160.50. In terms of profitability, TMDX's ROE is +0.33%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, TMDX is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ATEC's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ENOV trades at $24.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ENOV's P/E ratio is 7.07. In terms of profitability, TMDX's ROE is +0.33%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, TMDX is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ENOV's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while AORT trades at $28.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas AORT's P/E ratio is 47.72. In terms of profitability, TMDX's ROE is +0.33%, compared to AORT's ROE of -0.01%. Regarding short-term risk, TMDX is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check AORT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while IART trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas IART's P/E ratio is 7.36. In terms of profitability, TMDX's ROE is +0.33%, compared to IART's ROE of -0.01%. Regarding short-term risk, TMDX is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check IART's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas HSKA's P/E ratio is -62.49. In terms of profitability, TMDX's ROE is +0.33%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, TMDX is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check HSKA's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while PRCT trades at $21.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas PRCT's P/E ratio is -10.95. In terms of profitability, TMDX's ROE is +0.33%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, TMDX is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PRCT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas AVNS's P/E ratio is 27.77. In terms of profitability, TMDX's ROE is +0.33%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, TMDX is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check AVNS's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while LMRI trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas LMRI's P/E ratio is -22.82. In terms of profitability, TMDX's ROE is +0.33%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, TMDX is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check LMRI's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while IRMD trades at $87.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas IRMD's P/E ratio is 43.92. In terms of profitability, TMDX's ROE is +0.33%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, TMDX is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check IRMD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SILK's P/E ratio is -18.96. In terms of profitability, TMDX's ROE is +0.33%, compared to SILK's ROE of -0.35%. Regarding short-term risk, TMDX is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SILK's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas FNA's P/E ratio is -19.83. In terms of profitability, TMDX's ROE is +0.33%, compared to FNA's ROE of -0.35%. Regarding short-term risk, TMDX is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check FNA's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BVS has a market cap of 942.7M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BVS trades at $13.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BVS's P/E ratio is 18.31. In terms of profitability, TMDX's ROE is +0.33%, compared to BVS's ROE of +0.28%. Regarding short-term risk, TMDX is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BVS's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, INMD has a market cap of 875.4M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while INMD trades at $15.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas INMD's P/E ratio is 10.58. In terms of profitability, TMDX's ROE is +0.33%, compared to INMD's ROE of +0.12%. Regarding short-term risk, TMDX is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check INMD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CBLL has a market cap of 869.3M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CBLL trades at $22.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CBLL's P/E ratio is -14.06. In terms of profitability, TMDX's ROE is +0.33%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, TMDX is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CBLL's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, AVR has a market cap of 862.4M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while AVR trades at $8.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas AVR's P/E ratio is -3.98. In terms of profitability, TMDX's ROE is +0.33%, compared to AVR's ROE of -0.78%. Regarding short-term risk, TMDX is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check AVR's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CSII's P/E ratio is -20.83. In terms of profitability, TMDX's ROE is +0.33%, compared to CSII's ROE of -0.14%. Regarding short-term risk, TMDX is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check CSII's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SIBN has a market cap of 842.6M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SIBN trades at $19.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SIBN's P/E ratio is -55.88. In terms of profitability, TMDX's ROE is +0.33%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, TMDX is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check SIBN's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, AHCO has a market cap of 785M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while AHCO trades at $5.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas AHCO's P/E ratio is 11.78. In terms of profitability, TMDX's ROE is +0.33%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, TMDX is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check AHCO's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BBNX has a market cap of 779.7M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BBNX trades at $17.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BBNX's P/E ratio is -11.48. In terms of profitability, TMDX's ROE is +0.33%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, TMDX is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BBNX's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while VREX trades at $18.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas VREX's P/E ratio is 19.42. In terms of profitability, TMDX's ROE is +0.33%, compared to VREX's ROE of +0.05%. Regarding short-term risk, TMDX is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check VREX's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SSII has a market cap of 738.5M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SSII trades at $3.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SSII's P/E ratio is -71.97. In terms of profitability, TMDX's ROE is +0.33%, compared to SSII's ROE of -0.23%. Regarding short-term risk, TMDX is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check SSII's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BWAY has a market cap of 651.1M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BWAY trades at $16.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BWAY's P/E ratio is 42.17. In terms of profitability, TMDX's ROE is +0.33%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, TMDX is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BWAY's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, KIDS has a market cap of 638.5M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while KIDS trades at $24.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas KIDS's P/E ratio is -21.07. In terms of profitability, TMDX's ROE is +0.33%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, TMDX is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check KIDS's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SRDX's P/E ratio is -34.66. In terms of profitability, TMDX's ROE is +0.33%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, TMDX is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SRDX's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CTKB has a market cap of 612.1M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CTKB trades at $4.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CTKB's P/E ratio is -25.11. In terms of profitability, TMDX's ROE is +0.33%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, TMDX is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CTKB's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, DCTH has a market cap of 590.7M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while DCTH trades at $17.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas DCTH's P/E ratio is 1711.00. In terms of profitability, TMDX's ROE is +0.33%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, TMDX is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check DCTH's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas APEN's P/E ratio is -9.43. In terms of profitability, TMDX's ROE is +0.33%, compared to APEN's ROE of -0.85%. Regarding short-term risk, TMDX is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check APEN's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, TCMD has a market cap of 552.9M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while TCMD trades at $24.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas TCMD's P/E ratio is 27.85. In terms of profitability, TMDX's ROE is +0.33%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, TMDX is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check TCMD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CERS has a market cap of 546.1M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CERS trades at $2.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CERS's P/E ratio is -54.09. In terms of profitability, TMDX's ROE is +0.33%, compared to CERS's ROE of -0.10%. Regarding short-term risk, TMDX is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CERS's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, TMDX's ROE is +0.33%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, TMDX is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ZIMV's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, NPCE has a market cap of 496.4M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while NPCE trades at $14.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas NPCE's P/E ratio is -22.40. In terms of profitability, TMDX's ROE is +0.33%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, TMDX is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check NPCE's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SGHT has a market cap of 450.5M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SGHT trades at $8.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SGHT's P/E ratio is -14.79. In terms of profitability, TMDX's ROE is +0.33%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, TMDX is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check SGHT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CLPT has a market cap of 446.8M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CLPT trades at $15.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CLPT's P/E ratio is -12.63. In terms of profitability, TMDX's ROE is +0.33%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, TMDX is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CLPT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, OFIX has a market cap of 420.4M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while OFIX trades at $10.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas OFIX's P/E ratio is -13.59. In terms of profitability, TMDX's ROE is +0.33%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, TMDX is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check OFIX's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CATX has a market cap of 373.5M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CATX trades at $3.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CATX's P/E ratio is -2.32. In terms of profitability, TMDX's ROE is +0.33%, compared to CATX's ROE of -0.42%. Regarding short-term risk, TMDX is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CATX's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CARL has a market cap of 373M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CARL trades at $13.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CARL's P/E ratio is -9.59. In terms of profitability, TMDX's ROE is +0.33%, compared to CARL's ROE of -0.38%. Regarding short-term risk, TMDX is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CARL's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, TLSI has a market cap of 351.6M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while TLSI trades at $5.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas TLSI's P/E ratio is -3.40. In terms of profitability, TMDX's ROE is +0.33%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, TMDX is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check TLSI's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ELMD has a market cap of 351.5M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ELMD trades at $42.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ELMD's P/E ratio is 36.28. In terms of profitability, TMDX's ROE is +0.33%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, TMDX is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ELMD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, PMI has a market cap of 349.2M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while PMI trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas PMI's P/E ratio is -2.83. In terms of profitability, TMDX's ROE is +0.33%, compared to PMI's ROE of +4.99%. Regarding short-term risk, TMDX is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PMI's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, PACB has a market cap of 344.8M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while PACB trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas PACB's P/E ratio is -2.71. In terms of profitability, TMDX's ROE is +0.33%, compared to PACB's ROE of -49.62%. Regarding short-term risk, TMDX is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PACB's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SENS has a market cap of 331.4M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SENS trades at $7.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SENS's P/E ratio is -3.96. In terms of profitability, TMDX's ROE is +0.33%, compared to SENS's ROE of -1.66%. Regarding short-term risk, TMDX is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check SENS's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, CV has a market cap of 329.8M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while CV trades at $6.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas CV's P/E ratio is -2.64. In terms of profitability, TMDX's ROE is +0.33%, compared to CV's ROE of +1.27%. Regarding short-term risk, TMDX is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check CV's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas SMLR's P/E ratio is 3.92. In terms of profitability, TMDX's ROE is +0.33%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, TMDX is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check SMLR's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, TMCI has a market cap of 308.1M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while TMCI trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas TMCI's P/E ratio is -5.05. In terms of profitability, TMDX's ROE is +0.33%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, TMDX is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check TMCI's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ANIK has a market cap of 294.8M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ANIK trades at $22.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ANIK's P/E ratio is 44.96. In terms of profitability, TMDX's ROE is +0.33%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, TMDX is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check ANIK's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, RXST has a market cap of 292.3M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while RXST trades at $7.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas RXST's P/E ratio is -7.59. In terms of profitability, TMDX's ROE is +0.33%, compared to RXST's ROE of -0.17%. Regarding short-term risk, TMDX is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check RXST's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, PROF has a market cap of 251.8M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while PROF trades at $6.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas PROF's P/E ratio is -5.59. In terms of profitability, TMDX's ROE is +0.33%, compared to PROF's ROE of -0.56%. Regarding short-term risk, TMDX is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check PROF's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas MGRM's P/E ratio is -12.00. In terms of profitability, TMDX's ROE is +0.33%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, TMDX is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check MGRM's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas NVRO's P/E ratio is -1.91. In terms of profitability, TMDX's ROE is +0.33%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, TMDX is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check NVRO's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, STIM has a market cap of 223.4M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while STIM trades at $3.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas STIM's P/E ratio is -5.94. In terms of profitability, TMDX's ROE is +0.33%, compared to STIM's ROE of -1.51%. Regarding short-term risk, TMDX is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check STIM's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, RCEL has a market cap of 201.7M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while RCEL trades at $8.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas RCEL's P/E ratio is -5.17. In terms of profitability, TMDX's ROE is +0.33%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, TMDX is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check RCEL's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas BSGM's P/E ratio is -5.81. In terms of profitability, TMDX's ROE is +0.33%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, TMDX is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check BSGM's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, LUCD has a market cap of 187.8M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while LUCD trades at $0.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas LUCD's P/E ratio is -2.66. In terms of profitability, TMDX's ROE is +0.33%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, TMDX is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check LUCD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas MDGS's P/E ratio is -0.27. In terms of profitability, TMDX's ROE is +0.33%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, TMDX is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check MDGS's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, FOCL has a market cap of 178M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while FOCL trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas FOCL's P/E ratio is -5.80. In terms of profitability, TMDX's ROE is +0.33%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, TMDX is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check FOCL's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas QIPT's P/E ratio is -15.87. In terms of profitability, TMDX's ROE is +0.33%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, TMDX is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check QIPT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, INGN has a market cap of 157.3M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while INGN trades at $5.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas INGN's P/E ratio is -6.38. In terms of profitability, TMDX's ROE is +0.33%, compared to INGN's ROE of -0.13%. Regarding short-term risk, TMDX is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check INGN's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, QTRX has a market cap of 138M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while QTRX trades at $2.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas QTRX's P/E ratio is -1.83. In terms of profitability, TMDX's ROE is +0.33%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, TMDX is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check QTRX's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas ICAD's P/E ratio is -20.37. In terms of profitability, TMDX's ROE is +0.33%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, TMDX is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check ICAD's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, OWLT has a market cap of 105.9M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while OWLT trades at $5.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas OWLT's P/E ratio is -41.79. In terms of profitability, TMDX's ROE is +0.33%, compared to OWLT's ROE of -0.74%. Regarding short-term risk, TMDX is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check OWLT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, HSDT has a market cap of 101.6M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while HSDT trades at $1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas HSDT's P/E ratio is -0.02. In terms of profitability, TMDX's ROE is +0.33%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, TMDX is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for TMDX.Check HSDT's competition here

TransMedics Group, Inc. (NASDAQ: TMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMDX stands at 3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, TMDX is priced at $87.02 on the NASDAQ, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMDX currently has a P/E ratio of 44.17, whereas HJLI's P/E ratio is N/A. In terms of profitability, TMDX's ROE is +0.33%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, TMDX is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for TMDX.Check HJLI's competition here